Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cytarabine × Tumor-Agnostic × Clear all

Phase

Phase NA 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 335 Lymphoid 230 Myeloid 63 Classical hematology 19 Sarcoma 16 Plasma cell 10 CNS 6 Tumor-Agnostic 1 Other solid neoplasm 1 Genitourinary 1 Dermatologic 1

Conditions

Neoplasm, Residual 1 Neoplasm Metastasis 1

Interventions

Gemcitabine 26 Paclitaxel 24 pembrolizumab 23 Carboplatin 22 Bevacizumab 18 Radiotherapy 16 Oxaliplatin 16 Erlotinib Hydrochloride 16 Nivolumab 15 Cisplatin 14 Capecitabine 14 Fluorouracil 13 Trastuzumab 12 Docetaxel 12 atezolizumab 11 Magnetic Resonance Spectroscopy 11 Leucovorin 11 Cyclophosphamide 11 Irinotecan 10 Ipilimumab 10 Vemurafenib 9 Everolimus 9 Cetuximab 9 cabozantinib 8 Radiosurgery 8 Afatinib 8 130-nm albumin-bound paclitaxel 8 trametinib 7 lenvatinib 7 durvalumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02067143 2021-09-08

LAL1913

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed

Neoplasm Metastasis, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡